Onychomycosis in the Gdansk area in Poland

Petranyuk, Andriy; Bykowska, Barbara; Wilkowska, Aleksandra; Nowicki, Roman

doi:10.5114/dr.2021.110798

Cited by 1 publication

(1 citation statement)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Sufficient data were available to compare the prevalence of NDM onychomycosis in clinically suspected patients who underwent single ( n = 81,515) or repeat sampling ( n = 32,171) 16,50–112 . Across both Global North and Global South regions, results from studies where single sampling is performed showed a higher degree of variability compared to studies that utilized the recommended repeat sampling approach (Figure 3).…”

Section: Resultsmentioning

confidence: 99%

Global prevalence of onychomycosis in general and special populations: An updated perspective

Gupta,

Wang,

Polla Ravi

et al. 2024

Mycoses

View full text Add to dashboard Cite

BackgroundOnychomycosis is a chronic nail disorder commonly seen by healthcare providers; toenail involvement in particular presents a treatment challenge.ObjectiveTo provide an updated estimate on the prevalence of toenail onychomycosis.MethodsWe conducted a literature search using PubMed, Embase and Web of Science. Studies reporting mycology‐confirmed diagnoses were included and stratified into (a) populations‐based studies, and studies that included (b) clinically un‐suspected and (c) clinically suspected patients.ResultsA total of 108 studies were included. Based on studies that examined clinically un‐suspected patients (i.e., with or without clinical features suggestive of onychomycosis), the pooled prevalence rate of toenail onychomycosis caused by dermatophytes was 4% (95% CI: 3–5) among the general population; special populations with a heightened risk include knee osteoarthritis patients (RR: 14.6 [95% CI: 13.0–16.5]), chronic venous disease patients (RR: 5.6 [95% CI: 3.7–8.1]), renal transplant patients (RR: 4.7 [95% CI: 3.3–6.5]), geriatric patients (RR: 4.7 [95% CI: 4.4–4.9]), HIV‐positive patients (RR: 3.7 [95% CI: 2.9–4.7]), lupus erythematosus patients (RR: 3.1 [95% CI: 1.2–6.3]), diabetic patients (RR: 2.8 [95% CI: 2.4–3.3]) and hemodialysis patients (RR: 2.8 [95% CI: 1.9–4.0]). The prevalence of onychomycosis in clinically suspected patients was significantly higher likely due to sampling bias. A high degree of variability was found in a limited number of population‐based studies indicating that certain pockets of the population may be more predisposed to onychomycosis. The diagnosis of non‐dermatophyte mould onychomycosis requires repeat sampling to rule out contaminants or commensal organisms; a significant difference was found between studies that performed single sampling versus repeat sampling. The advent of PCR diagnosis results in improved detection rates for dermatophytes compared to culture.ConclusionOnychomycosis is an underrecognized healthcare burden. Further population‐based studies using standardized PCR methods are warranted.

show abstract

Section: Resultsmentioning

confidence: 99%